ArticleJournal of hepatocellular carcinoma2026
Efficacy and Safety of TACE-HAIC Combined with Molecular Targeted Therapy and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy and safety of a quadruple regimen of transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) plus molecular targeted therapy (MTT) and immune checkpoint inhibitors (ICIs) for unresectable hepatocellular carcinoma (uHCC). Patients and Methods: 274 uHCC patients were divided into two groups based on two treatment methods:TACE-HAIC combined with MTT and ICIs (THTI) and TACE combined with MTT and ICIs (TTI). The primary endpoints were progression-free survival (PFS) and overall survival (OS). The secondary endpoints included the objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (TRAEs). Results: After Propensity score matching (PSM), the THTI group significantly prolonged median PFS (14.0 vs 10.6 months, P< 0.001) and median OS (30.8 vs 24.8 months, P = 0.001) compared with the TTI group. Compared with the TTI group, the THTI group demonstrated significantly superior ORR (64.5% vs 44.9%, P=0.004) and DCR (94.4% vs 84.1%, P=0.015). In addition, responses to THTI (THTI-R) had superior median PFS (17.1 vs 13.8 months, P = 0.007) and median OS (38.1 vs 27.5 months, P = 0.002) versus responses to TTI (TTI-R). All adverse events were manageable in two groups. Conclusion: For patients with uHCC, the THTI quadruple therapy demonstrated a superior clinical benefit over current TTI triple therapy, including significant prolongation of both PFS and OS, as well as improvements in ORR and DCR, with a manageable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.